AMEX Notifies Signalife That It Has Accepted Signalife's Plan of Compliance

GREENVILLE, S.C., March 20 On January 7, 2008,Signalife received a deficiency letter from the American Stock Exchange("AMEX") pursuant to which it advised that Signalife would need to comply withthe $6 million stockholders' equity threshold required for continued listingunder AMEX Rules 1003(a)(iii). This notification was triggered by the declineof Signalife's market capitalization to less than $50 million, whichpreviously exempted Signalife from meeting the minimum stockholders' equityrequirement. Pursuant to the letter, Signalife submitted to AMEX for itsreview and acceptance a plan to bring the company into compliance with theaforesaid stockholders' equity requirement. On March 20, 2008, AMEX notifiedSignalife that it accepted the company's plan of compliance and granted thecompany an extension until May 7, 2009 to regain compliance with the aforesaidstockholders' equity requirement. Signalife will be subject to periodicreview by AMEX Staff during this extension period. Failure to make progressconsistent with the plan or to otherwise regain compliance with the aforesaidstockholders' equity requirement by the end of the extension period couldresult in the company being delisted from AMEX.

About Signalife, Inc.

Signalife, Inc. is a life sciences company focused on the monitoring anddetection of disease through continuous biomedical signal monitoring.Signalife uses its patented signal technology to design and develop medicaldevices that simplify and reduce the costs of diagnostic testing and patientmonitoring in an ambulatory setting. Signalife, Inc. is the recipient of theFrost & Sullivan Technological Innovation Award for 2006 and 2008.

Signalife, Inc. is traded on the American Stock Exchange under the symbolSGN. More information is located at www.signalife.com. Clear Data. TrustedResults.

Caution Regarding Forward-Looking Statements

In this news release we make a number of statements, referred to as"forward-looking statements", which are intended to convey our expectations orpredictions regarding the occurrence of possible future events or theexistence of trends and factors that may impact our future plans and operatingresults. Any statements in this news release that are not statements ofhistorical fact maybe considered to be forward-looking statements. Theseforward-looking statements are derived, in part, from various assumptions andanalyses we have made in the context of our current business plan andinformation currently available to us and in light of our experience andperceptions of historical trends, current conditions and expected futuredevelopments and other factors we believe to be appropriate in thecircumstances. You can generally identify forward-looking statements throughwords and phrases such as "seek", "anticipate", "believe", "estimate","expect", "intend", "plan", "budget", "project", "may be", "may continue","may likely result", and similar expressions. Each forward-looking statementshould be read in context with, and with an understanding of, the variousother disclosures concerning our company and our business made in this newsrelease as well as other public reports we file with the SEC, as they may beamended. You should not place undue reliance on any forward-looking statementas a prediction of actual results or developments. For example, no assurancecan be given that Signalife will attain the results set forth in the plan orotherwise satisfy AMEX's continued listing requirements, or that Signalife'scommon stock will continue to trade on AMEX. We are not obligated to updateor revise any forward-looking statement contained in this news release toreflect new events or circumstances unless and to the extent required byapplicable law.

SOURCE Signalife, Inc.

Latest Press Release on General News

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...

A 2017 Hyundai Elantra and 760,000 kilometres of life-saving blood donation deliveries

Mr. Tim German's 2017 Hyundai Elantra a.k.a. "Dark Angel," was bought new from Steele Hyundai Halifax and now has more than 760,000 kilometres on the odometer. With his Elantra, Mr....

Philips Respironics Reaches Agreement with US Government on a Consent Decree Creating a Clear Path Forward

April 10, 2024 Philips confirms that further to communicating the main terms of the Philips Respironics consent decree on January 29, 2024, Philips’ subsidiaries Philips Holding USA ...